Pacira BioSciences, Inc. (PCRX)

NASDAQ

$26.69

+$0.40 (1.52%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$26.29$27.07

Open $26.29

52 Week Range

$18.17$27.64

Previous Close $26.29

Market Cap1.21B

Volume974.75K

Avg Volume731.93K

P/E (TTM)39.68

EPS (TTM)$0.67

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Pacira BioSciences, Inc.

DEC32025

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•12 days ago

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement a...

NOV262025

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

Source: GlobeNewsWire•19 days ago

-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to tra...

NOV112025

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Source: GlobeNewsWire•34 days ago

BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will parti...

NOV102025

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Source: PRNewsWire•35 days ago

DOMA Controls 6.8% of Pacira Common Stock MIAMI , Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira"), today sent a letter to the Board of Directors of P...

NOV62025

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Source: GlobeNewsWire•39 days ago

-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif....

NOV52025

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Source: GlobeNewsWire•40 days ago

-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasda...

NOV42025

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

Source: GlobeNewsWire•41 days ago

-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 --...

OCT302025

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Source: GlobeNewsWire•46 days ago

BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will repor...

OCT272025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Source: GlobeNewsWire•49 days ago

BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Pa...

OCT232025

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Source: GlobeNewsWire•53 days ago

-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the live...